Format

Send to

Choose Destination
Paediatr Respir Rev. 2016 Aug;20 Suppl:24-6. doi: 10.1016/j.prrv.2016.06.010. Epub 2016 Jun 15.

Is deafness mutation screening required in cystic fibrosis patients?

Author information

1
Department of Paediatrics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: r.abusamra@nhs.net.
2
Department of Paediatrics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Abstract

Aminoglycosides are widely used in cystic fibrosis management. The m.1555A>G mutation predisposes to aminoglycoside ototoxicity. It may cause later onset hearing loss in the absence of aminoglycosides use and gradual hearing loss may be an inevitable consequence of the mutation. Given that aminoglycoside therapy forms the backbone of IV protocols in CF, this article recommends screening for this mutation to allow informed decision-making prior to aminoglycoside administration, to avoid preventable deafness.

KEYWORDS:

Aminoglycosides; Cystic fibrosis; Hearing loss; Mitochondrial mutation m.1555A>G.

PMID:
27427311
DOI:
10.1016/j.prrv.2016.06.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center